Raising the bar: the curative potential of human cancer immunotherapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22461638.
- Also identified by DOI 10.1126/scitranslmed.3003634 and PMC identifier 6292198.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.
Medical subject headings
- Immunotherapy
- Neoplasms